Mark this date:
On May 29th , 2026...
The biggest scam in the history of gold markets will be exposed...
It's the math that keeps bankers up at night...
The gold chart that has Wall Street shaking in its loafers...
That's the day the public will see that their gold ETFs are nothing but paper...
The rush from ETFs to real assets will be unlike anything we've seen in 300 years.
One stock on the receiving end of this epic transfer, is set to explode 1,000% as ETF holders could get wiped out.
This isn't a hunch - it's math.
See all the evidence for yourself right here and take your position before it's too late.
"The Buck Stops Here,"
Dylan Jovine
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
Submitted by Jeffrey Neal Johnson. Published: 4/7/2026.
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings.
For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Hey, Have You Claimed Your Rebate Check?? (Ad)
The U.S. has already collected $195 billion in tariff revenue this year, with projections reaching $400 billion by 2026 - drawn from over 90 countries.
Investment Director Jason Williams says a portion of that revenue is being channeled into what he calls 'Tariff Rebate Checks' - quarterly payouts potentially worth up to $8,276. The next payout window is approaching.
See the full briefing on how to claim your position todayAbbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 during the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking.
A closer look at Abbott Laboratories’ situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors?
Separating the Signal From the Noise
A stock like Abbott rarely falls without reason. Its recent decline stems from two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, largely caused by U.S. pediatric market-share losses and pricing dynamics that constrained volume. Management has been candid about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford detailed price and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, forecasting a return to growth in the second half of the year.
The second factor is external and broader in scope. The market has been undergoing a significant rotation of capital: in periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. This broad trend has weighed on many fundamentally sound healthcare companies, including Abbott, depressing their share prices for reasons largely unrelated to their individual performance or long-term prospects.
Abbott’s Engine Room Is Running Strong
While the Nutrition segment navigates a short-term recovery, Abbott's core remains exceptionally strong, led by its largest and most profitable division: Medical Devices. This segment is not just stable — it is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in nutrition, and the company’s true health is most evident in these high-performing areas.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care categories.
Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. This product line, which lets users track glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success.
Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit clip, while its Structural Heart business posted strong organic growth of 8.7%. That strength comes from a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive heart valve repair solutions, along with a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation.
Abbott is not relying solely on its existing portfolio. It is making a major strategic move to secure future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard.
The deal would position Abbott as a leader in the rapidly expanding cancer diagnostics market, adding a new, high-growth vertical likely to contribute meaningfully to revenue for years to come.
This bullish view is shared by Wall Street. Analysts hold a Moderate Buy consensus rating on the stock, and the average 12-month price target is $135.47 — implying potential upside of more than 30% from current levels.
A Bedrock of Reliability for Income Investors
For long-term investors focused on income, Abbott’s dividend is a standout feature.
Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record signals a deep commitment to returning capital to shareholders across market cycles.
The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current levels, Abbott yields about 2.5%, allowing investors to secure a stronger income rate from a historically reliable payer. The dividend also appears secure: the payout ratio is roughly 68% of earnings and represents about 37% of operating cash flow, suggesting the company generates ample cash to cover dividends with room for future increases.
A Disconnect Between Price and Value
Current market sentiment around Abbott seems disconnected from its business reality. Temporary headwinds in a single division and broader market rotation have depressed the stock price, yet Abbott’s fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a bedrock of reliability, and strategic catalysts like the Exact Sciences acquisition could add meaningful growth. For investors with a long-term horizon, the present valuation highlights a noteworthy gap between price and intrinsic value — an opportunity worth serious consideration.
3 Healthcare Stocks Providing Relief for the Sandwich Generation
Author: Chris Markoch. First Published: 4/10/2026.
Key Points
- Omega Healthcare Investors offers income investors a 5.8% yield backed by rising demand for senior housing and skilled nursing facilities.
- Addus HomeCare provides direct exposure to the fast-growing home healthcare market with strong earnings growth and over 40% implied upside.
- Savaria taps into the aging-in-place trend with accessibility solutions and a monthly dividend, making it a unique growth and income play.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The aging of America remains an investable theme, and recent AARP survey data offers investors a clue on where to direct capital.
According to AARP, about 59 million Americans provided care for an adult family member, neighbor, or friend in 2024. That totaled 49.5 billion hours of care—about $1.01 trillion in annual economic value—a figure that exceeds combined federal, state, and local Medicaid spending.
Caregivers in the “sandwich generation”—typically in their 40s to early 60s—often balance raising children, caring for elderly relatives, and managing careers.
Hey, Have You Claimed Your Rebate Check?? (Ad)
The U.S. has already collected $195 billion in tariff revenue this year, with projections reaching $400 billion by 2026 - drawn from over 90 countries.
Investment Director Jason Williams says a portion of that revenue is being channeled into what he calls 'Tariff Rebate Checks' - quarterly payouts potentially worth up to $8,276. The next payout window is approaching.
See the full briefing on how to claim your position todayInformal caregiving is often a more affordable alternative to institutional or assisted-living arrangements, which either require Medicaid approval for those who qualify or impose significant out-of-pocket costs for those who do not.
The U.S. Census Bureau projects the 65-and-older population will nearly double by 2060. That is why investors should consider healthcare stocks with business models that help relieve caregivers.
Omega Healthcare Investors Delivers Income as Senior Housing Demand Rebounds
Omega Healthcare Investors (NYSE: OHI) is a real estate investment trust (REIT) that owns and manages healthcare-related properties, including skilled nursing facilities and assisted living communities. It acquires and leases these properties under triple-net agreements, providing investors with relatively stable, inflation-protected cash flow.
According to the National Investment Center for Seniors Housing & Care, occupancy rates for senior housing, assisted living, and independent living are nearly back to pre-pandemic levels, suggesting that demand for those services is strengthening.
After a nearly 25% gain over the past 12 months, much of that growth appears priced in. A moderate pullback last month improves the buy case. Analysts have raised price targets, but the consensus price target of $48 is only slightly higher than OHI’s current share price as of this writing.
Many investors turn to REITs for reliable dividends. In Omega Healthcare’s case, the dividend yield is 5.8%, and it appears sustainable based on future earnings and cash flow estimates.
Addus HomeCare Is Positioned for Growth as In-Home Care Gains Traction
Addus HomeCare (NASDAQ: ADUS) focuses on the growing need for home health care. The company is a leading provider of home- and community-based care services, operating through a mix of company-owned and franchise locations across the United States.
Shares of ADUS are down about 7% over the past year, which may reflect the company’s ongoing efforts with states to secure Medicaid funding. Addus has argued that personal care is often materially less expensive than nursing home placement, conserving Medicaid dollars.
The company recently noted that Medicaid redeterminations are easing, which could provide a tailwind.
Addus has posted year-over-year revenue and earnings growth in recent quarters, and analysts forecast more than 16% earnings growth over the next 12 months.
Despite a solid earnings report in November, ADUS sold off sharply and is trading near its 52-week low—an entry point some investors may view as an opportunity. Analysts are broadly bullish, with a consensus price target more than 40% above recent prices. The stock currently carries a Moderate Buy rating.
Savaria Capitalizes on Aging-in-Place Trend With Accessibility Solutions
Savaria (OTCMKTS: SISXF) sits between the industrial and medical sectors. The company sells home-accessibility products—stairlifts, elevators, and platform lifts—that support the aging-in-place market.
Savaria’s products are a common first step for families and caregivers who modify a loved one’s home before considering alternate living or care arrangements.
That demand shows up in the company’s revenue and earnings estimates and helps explain why SISXF is up more than 90% over the past 12 months. The Canada-based company has limited analyst coverage, but MarketBeat’s data shows a Buy rating.
SISXF also pays a monthly dividend—4.67 cents per share in March 2026—which may appeal to investors seeking income alongside growth potential.
This email content is a sponsored email provided by Behind the Markets, a third-party advertiser of The Early Bird and MarketBeat.
If you need assistance with your newsletter, please don't hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl. #620, Sioux Falls, SD 57103-7078. USA..